Trials / Terminated
TerminatedNCT00954993
Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)
A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Following Administration of MK-7009 in Hepatitis C Infected Patients
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the hepatic (liver) and plasma pharmacokinetics of Vaniprevir (MK-7009) by evaluation of ribonucleic acid (RNA) of the hepatitis C virus (HCV) in genotype 1, HCV-infected participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vaniprevir | Period 1: Vaniprevir 600 mg twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg on Day 4. Period 2: Vaniprevir 300 mg twice daily on Days 1-3 and a single dose of Vaniprevir 300 mg on Day 4. There was at least a 30-day (up to approximately 140-day) washout interval between periods 1 and 2. |
Timeline
- Start date
- 2010-01-13
- Primary completion
- 2011-03-04
- Completion
- 2011-03-04
- First posted
- 2009-08-07
- Last updated
- 2018-10-18
- Results posted
- 2014-09-29
Source: ClinicalTrials.gov record NCT00954993. Inclusion in this directory is not an endorsement.